| First author [ref.] | Country | IGRA | TST cut-off mm# | Participants n | IMID condition | BCG % | Indeterminate % | κ | Concordant results | Discordant results | ||
| TST+/IGRA+ n (%) | TST-/IGRA-n (%) | TST-/IGRA+ n (%) | TST+/IGRA- n (%) | |||||||||
| Cobanoglu 143 | Turkey | QFT-G IT | 10 | 68 cases38 controls | >65% RA+AS | 100 | 10.35.3 | 0.14-0.05 | 8 (13.1) 0 | 23 (37.7)23 (63.8) | 1 (1.6)1 (2.8) | 29 (47.5)12 (33.3) |
| Matulis 144¶ | Switzerland | QFT-G IT | 5 | 142 | >65% RA+SA | 83 | 6 | 0.16 | 10 (7) | 60 (44.7) | 5 (3.5) | 34 (25.4) |
| Dinser 132 | Germany | Flow cytometric assay | 5 | 97 | >50% RA | 5.1 | 0 | 0.31 | 6 (6.2) | 74 (76.3) | 10 (10.3) | 7 (7.2) |
| Ponce de Leon 145 | Peru | QFT-G IT | 5 | 101 cases93 controls | RA | 80.2 80.6 | 1.90 | 0.370.55 | 21 (20.8)16 (17.2) | 50 (49.5)61 (65.6) | 24 (23.8)5 (5.4) | 6 (5.9)11 (11.8) |
| Vassiloupolos 146 | Greece | T-SPOT.TB | 5 | 70 | >85% RA+AS+PA | 40 | 0 | 0.38 | 12 (17.1) | 39 (55.7) | 4 (5.7) | 15 (21.5) |
| Bocchino 147 | Italy | QFT-G IT T-SPOT.TB | 5 | 6969 | RA+IBD+PA | 2.8 | 2.85.8 | 0.570.48 | 14 (20.9)12 (18.5) | 41 (61.2)39 (60) | 8 (11.9) (13.8) | 4 (6)5 (7.7) |
| Bartalesi 148 | Italy | QFT-G IT | ƒ | 398 | >85% RA+PA+AS | 4.1 | 1.5 | 0.55 | 39 (10) | 306 (77.8) | 13 (3.3) | 35 (8.9) |
| Murakami 149 | Japan | ELISPOT§ | 5 | 71 | RA | 100 | 0 | 0.18 | 4 (5.7) | 50 (71.4) | 6 (8.4) | 11 (15.5) |
| Martin 150+ | Ireland | T-SPOT.TB QFT-G | 5 | 15072 | RA+PA+AS | 82 | 4.72.8 | 0.2NA++ | 6 (4.2)NA++ | 110 (77)NA++ | 8 (5.6)NA++ | 19 (13.2)NA++ |
| Behar 151 | USA | T-SPOT.TB | 5## | 179 | >80% RA | 4.7 | 0 | -0.019 | 0 (0) | 167 (93.3) | 10 (5.6) | 2 (1.1) |
| Laffitte 152 | Switzerland | T-SPOT.TB | 5 | 50 | SP | 90 | 0 | 0.33 | 8 (16) | 28 (56) | 2 (4) | 12 (24) |
| Soborg 153 | Denmark | QFT-G | ¶¶ | 234 | >50% RA | 76 | 5 | 0.2 | 9 (4) | 180 (77) | 9 (4) | 36 (15) |
| Inanc 154 | Turkey | QFT-G | 5 | 140 | RA+AS | 84 | 5.7 | 0.29 | 41 (31) | 40 (30) | 5 (4) | 46 (35) |
BCG: bacillus Calmette–Guérin; QFT-G IT: QuantiFERON TB Gold In-tube; QFT-G: QuantiFERON TB Gold; RA: rheumatoid arthritis; AS: ankylosing spondylitis; SA: spondylarthropathies; PA: psoriatic arthritis; SP: severe psoriasis; IBD: inflammatory bowel disease; NA: not available. #: refers to the TST cut-off in the IMID subjects (and not in the controls, where present); ¶: TST analysed retrospectively; the median time between performing the TST and the QFT assay was 102 days (range 7–184 days); +: concordance between QFT-G and T-SPOT.TB 98.4% (agreement: k = 0.9); §: in-house ELISPOT with antigens CFP-10 and ESAT-6; ƒ: TST cut-off >5, >10 or >15, stratified by groups at risk and risk factors for Mycobacterium tuberculosis infection; ##: TST was read, after instruction, by the patients themselves; ¶¶: TST cut-off ≥12 for BCG vaccinated and ≥6 for unvaccinated; ++: data on discordant results between two tests not available.